Fed. Cir.

Forest Laboratories, LLC v. Sigmapharm Laboratories, LLC, No. 17-2369 (Fed. Cir. Mar. 14, 2019)

Claim Construction Invalidity (§ 102/§ 103) Non-Infringement

Court: U.S. Court of Appeals for the Federal Circuit
Case No.: No. 17-2369
Also Docketed: No. 17-2370, No. 17-2372, No. 17-2373, No. 17-2374, No. 17-2375, No. 17-2376, No. 17-2389, No. 17-2412, No. 17-2436, No. 17-2438, No. 17-2440, No. 17-2441 (consolidated; same document)
Decided: March 14, 2019
Judge: Moore, J.
Document: Precedential Opinion
Length: 16 pages

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Sigmapharm Laboratories, LLC, (“Sigmapharm”), Hikma Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, Hikma Pharmaceuticals USA Inc ., (collectively , “Hikma”), Breckenridge Pharmaceuticals Inc. (“B recken- ridge”), Alembic Pharmaceuticals Ltd., Alembic Global Holdings S.A., Alembic Pharmaceuticals Inc., (collectively, “Alembic”), Amneal Pharmaceuticals LLC, and Amneal Pharmaceuticals Co. India Pvt. Ltd.

Download Opinion (PDF)

Source: govinfo.gov USCOURTS collection · retrieved July 23, 2026 · Report an error